Breast cancer subtypes and survival in patients with brain metastases by Nam, Byung-Ho et al.
Open Access
Available online http://breast-cancer-research.com/content/10/1/R20
Page 1 of 8
(page number not for citation purposes)
Vol 10 No 1 Research article
Breast cancer subtypes and survival in patients with brain 
metastases
Byung-Ho Nam1*, Sun Young Kim1*, Hye-Sook Han1, Youngmee Kwon2, Keun Seok Lee2, 
Tae Hyun Kim3 and Jungsil Ro2
1Center for Clinical Trials, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea
2Center for Breast Cancer, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea
3Center for Proton Therapy, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea
* Contributed equally
Corresponding author: Jungsil Ro, jungsro@ncc.re.kr
Received: 31 Oct 2007 Revisions requested: 11 Dec 2007 Revisions received: 6 Jan 2008 Accepted: 28 Feb 2008 Published: 28 Feb 2008
Breast Cancer Research 2008, 10:R20 (doi:10.1186/bcr1870)
This article is online at: http://breast-cancer-research.com/content/10/1/R20
© 2008 Nam et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Brain metastases (BM) occur in up to one third of
patients with metastatic breast cancer (MBC), whose
incidences and prognoses by breast cancer subtypes in BM
have not been well delineated.
Methods Retrospective survival analyses were performed in
126 BM patients from 805 MBC patients treated at the National
Cancer Center between August 2001 and April 2006,
according to clinical characteristics, breast cancer subtypes,
and receipt of trastuzumab. Estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth
receptor-2 (HER2) statuses were tested by
immunohistochemical (IHC) staining, and HER2 FISH analysis
conducted for IHC 2+.
Results The proportion of HER2+/ER- (29% vs 16%) and
triple-negative (37% vs 25%) tumors was higher in the 126 BM
patients than those without BM. While median survival after
recurrence was longer in patients with luminal A disease
(median survival of luminal A vs luminal B vs HER2+/ER- vs
triple-negative: p = 0.0246; 39.6 vs 27.4 vs 20.9 vs 15.5
months), survival was shorter from BM to death in luminal A and
triple negatives (median survival: p = 0.0113; 4.0 vs 9.2 vs 5.0
vs 3.4 months). Receipt of trastuzumab after BM was a
significant variable for survival in HER2+ patients. Multivariate
analyses identified ER-negative, HER2-negative, or triple-
negative, as well as older age, presence of leptomeningeal
disease, and three or more extracranial disease sites, as poor
prognostic factors for survival after BM.
Conclusion MBC patients who developed BM had higher
proportions of triple-negative and HER2+/ER- tumor status.
Triple receptor status is a useful prognostic marker for
predicting survival after BM in metastatic breast cancer patients.
Introduction
Brain metastases (BM) clinically present in up to 16% of all
metastatic breast cancers (MBC), although autopsy series
reveal approximately twice as many cases (34%) [1,2]. Of the
patients with BM at autopsy, 19% are identified as having lep-
tomeningeal disease (LMD) [1]. Prognosis of BM is extremely
poor, and the median survival of BM patients ranges from 3 to
6 months [3], as it is usually a late event of systemic disease.
The general medical condition is often deteriorated by pro-
gressive neurological disabilities. Among several risk factors
identified in previous studies, negative estrogen receptor (ER)
or progesterone receptor (PR) [4-8] and human epidermal
growth factor receptor-2 (HER2) overexpression [6,9] have
been associated with a higher risk of development of BM.
Recent gene expression studies using DNA microarrays have
revealed the prognostic implication of breast cancer intrinsic
subtypes, including the basal-like, HER2+/ER-, and two types
of ER+ tumors: luminal A and luminal B subtypes [10,11].
Immunohistochemical (IHC) surrogates of these subtypes that
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were determined by IHC profiles of ER, PR, HER2, HER1 and
cytokeratin 5/6 were also studied. Although the definition
does not exactly coincide with that of gene-array-defined
intrinsic subtype, and only 30% to 50% of array-defined lumi-
nal B tumors are HER2+, the surrogate IHC subtypes were
also shown to be equally correlated with patient survival [12].
Based on the premise that the outcome of BM patients is
affected by the specific breast cancer intrinsic subtype, we
conducted the current study to analyze the prognostic signifi-
cance of clinical and biologic characteristics in correlation with
IHC tumor subtypes in BM patients with breast cancer.
Materials and methods
Study population
Between August 2001 and April 2006, a total of 805 meta-
static breast cancer patients were evaluated at the National
Cancer Center Hospital, Goyang, Korea. They were initially fol-
lowed up to October 2006. Of the 805 patients, 138 (17.1%)
presented symptomatic BM during their disease course. BM
was diagnosed by imaging studies with magnetic resonance
imaging or computed tomography and/or lumbar punctures.
Screening by brain imaging in asymptomatic patients is not
performed routinely at the National Cancer Center. The triple
receptor (ER, PR and HER2) status was known for 682 of the
805 metastatic breast cancer patients, including 126 of the
138 patients with BM. Another group of 118 serial patients,
who were diagnosed with early breast cancer (EBC) between
January 2002 and April 2003 with no evidence of recurrence
until October 2006, was screened for HER2 by fluorescence
in situ hybridization (FISH) and analyzed for their subtype sta-
tus. The proportion of breast cancer subtypes was compared
among three different disease subsets; patients with EBC (n
= 118), MBC without BM (n = 556), and MBC with BM (n =
126).
Patients with BM were followed up further to July 2007. The
medical records were retrospectively reviewed for the clinical
data, including age at the initial diagnosis and at BM, initial
stage of the disease, pathologic type, number and site of
extracranial metastases, disease-free interval, number of brain
metastatic lesions, presence of leptomeningeal disease, treat-
ment of BM, and survival from the onset of metastasis and from
the diagnosis of BM. This study protocol was approved by the
Institutional Review Board of the National Cancer Center (IRB
protocol number NCCNCS 07-093). Because this study was
a retrospective analysis that involved no more than minimal risk
for the subjects, the institutional review board approved our
request for the waiver of informed consent.
Immunohistochemistry and fluorescence in situ 
hybridization
IHC staining was performed on tissue sections cut from forma-
lin-fixed, paraffin-embedded representative breast tumors.
Staining was performed with the I-View DAB detection kit and
Ventana ES autostainer (Ventana Medical Systems, Tucson,
AZ, USA), using primary antibodies against ER (Ventana Med-
ical Systems), PR (Ventana Medical Systems) and a polyclonal
anti-HER2 oncoprotein (Herceptest; DAKO, Carpinteris, CA,
USA). For the evaluation of ER and PR expression, we
selected any focal positivity as weakly positive expression
[13]. For HER2 expression, only membranous staining was
scored according to HercepTest (DAKO) protocol criteria
[14].
FISH analysis was performed mostly on IHC 2+ tumors using
the PathVysion HER2 DNA Probe Kit (Vysis, Downers Grove,
IL, USA). HER2-positive staining was defined as IHC 3+ or, in
the case of IHC 2+, FISH positive. HER2-negativity was
defined as IHC 0, 1+ or 2+, along with negative FISH results.
If IHC staining or HER2-FISH was not available in the case of
IHC 2+, HER2 status was categorized as unknown. Due to
unknown ER, PR, or HER2 status, 12 out of 138 breast cancer
patients with BM were excluded for further analysis. HER2 sta-
tus was examined by FISH analysis for all the tumor samples
of the 118 EBC patients, and HER2 was considered positive
upon detection of HER2 amplification.
We divided the patients into four different breast cancer sub-
types: ER or PR+ and HER2-, ER or PR+ and HER2+, ER-
and PR- and HER2+, and ER- and PR- and HER2-. These sub-
types were referred to as luminal A, luminal B, HER2+/ER-,
and the triple-negative phenotype, respectively. The triple-neg-
ative phenotype was characterized by absence of staining for
ER, PR, and HER2 receptors, similar to the basal-like subtype,
which has added characteristics of positive staining for basal-
cell (myoepithelial) cytokeratins (CKs) 5/6 and/or HER1+
[12]. As we have not performed IHC for CK 5/6 and/or HER1,
all cases of ER-, PR- and HER2- were classified as showing a
triple-negative phenotype.
Treatment of brain metastases
Patients with BM were treated as indicated with at least one
of the following treatment modalities: whole brain radiotherapy
(WBRT), stereotactic radiotherapy, metastasectomy, or
intrathecal chemotherapy (IT). WBRT was performed at a
dose of 30 Gy (grays) in 10 fractions using a 6-MV photon by
two lateral opposed standard fields covering all intracranial
contents. Stereotactic radiotherapy was delivered with a 6-MV
photon coupled to a micro-multileaf collimator (3-mm width);
patients were immobilized with the fixation pins in a stereotac-
tic frame or a thermoplastic stereotactic head mask (Brain
LAB AG, Heimstetten, Germany). Tumors with a maximum
diameter of 3 cm or less were treated with dose of 15–22 Gy
with a single fraction, while tumors larger than 3 cm were
treated with dose of 36 Gy in 6 fractions, 5 times each week.
IT for patients with leptomeningeal disease was performed via
lumbar puncture or Ommaya reservoir with methotrexate (10–
15 mg twice a week) until malignant cells were cleared in the
cerebrospinal fluid.Available online http://breast-cancer-research.com/content/10/1/R20
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Statistical analyses
A chi-square test was performed to compare the incidence of
each breast cancer subtype in the three different patient sub-
sets: patients with EBC, MBC without BM, or MBC with BM.
Chi-square and Fisher's exact test were used for categorical
variables to compare the patient characteristics among the
four subtypes in 126 BM patients whose triple receptor sta-
tuses were known. A Kruskall-Wallis test was performed to
compare the median intervals among these four groups. The
overall survival from recurrence to death and from BM to death
was estimated using the Kaplan-Meier method and compared
using the log-rank test. The univariate and multivariate Cox
regression analyses were used to identify the independent
predictive factors that significantly influenced the overall sur-
vival from BM to death. All the statistical analyses were per-
formed using the STATA software, Version 9 (StataCorp,
College Station, TX, USA).
Results
Breast cancer subtypes according to disease status
The proportion of each IHC subtype according to the extent of
disease is shown in Table 1. The median follow times up to
October 2006 were 45.1 months for EBC group, 31.1 months
for MBC without BM group, and 26.2 months for BM group.
Each disease subset contained a different proportion of IHC
subtypes (p < 0.0001). While more than half of the EBC
patients were luminal A, the proportion of patients with
HER2+/ER- or triple-negative tumors was significantly higher
in the BM population compared to the EBC population, sug-
gesting that these subtypes were associated with the develop-
ment of BM. Notably, the proportion of luminal B tumors did
not change from the early stage to BM.
Clinical and tumor characteristics of patients with BM
The clinical features of the 126 patients with BM and the rela-
tionship with receptor status are presented in Table 2. In all,
23 tumors (18.3%) were luminal A tumors, 19 (15.1%) were
luminal B, 37 (29.4%) were HER2+/ER-, and 47 (37.3%)
were triple-negatives. Bone metastases were more frequent in
luminal A or B tumors compared with others subsets, while
other clinical characteristics were not significantly different
among the four subtypes.
Of the 126 patients with BM, 103 patients were treated with
WBRT, 3 with stereotactic radiotherapy only, 6 with IT only, 9
received WBRT with IT, 2 with metastatectomy (op) followed
by radiotherapy, and 2 with op only as initial therapy. One
patient chose symptomatic therapy only. Of the 56 HER2-pos-
itive patients, 10 patients did not receive trastuzumab, 25
completed trastuzumab therapy prior to BM diagnosis, and 21
patients received trastuzumab continuously before and after
the onset of BM, or only after BM diagnosed. No patients
received trastuzumab in the adjuvant setting.
Clinical outcome according to breast cancer subtypes
As of July 2007, 120 of 126 patients were deceased, and the
median age of all patients was 47 years (range, 22–70 years).
With a median follow-up of 56.0 months from recurrence, the
median survival of all patients from the time of recurrence to
death was 20.0 months (range, 0.1–131.0 months). The
median survival from recurrence varied depending on disease
subset, with patients with luminal A at 39.6 months, luminal B
at 27.4 months, HER2+/ER- at 20.9 months, and triple-nega-
tive tumors at 15.5 months (p = 0.0246, Figure 1a). With a
potential median follow-up of 34.8 months from brain
metastasis, the median survival for all patients was 4.5 months
(range, 0.1–43.9 months) from the brain metastasis to death.
Patients with ER+ or PR+ tumors lived significantly longer
after BM compared with ER- and PR- tumors (7.3 vs 3.8
months, p = 0.0439), as did patients with HER2-positive
tumors compared with HER2-negative tumors (6.7 vs 3.4
months, p = 0.0085). Survival after BM also significantly dif-
fered according to triple receptor status as determined by IHC
and/or FISH. Patients with luminal A (4.0 months) and triple-
negative tumors (3.4 months) had a similar shorter survival
time compared with luminal B (9.2 months) and HER2+/ER-
(5.0 months) tumors (p = 0.0113), as shown in Figure 1b.
Table 1
Breast cancer subtypes according to disease status.
IHC subtype No. (%) p Value†
Patients with EBC (n = 118) Patients with MBC* (n = 556) Patients with BM (n = 126)
Luminal A (ER or PR+/HER2-) 68 (57.6) 254 (46.7) 23 (18.3) < 0.0001
Luminal B (ER or PR+/HER2+) 16 (13.6) 73 (13.1) 19 (15.1)
HER2+/ER- (ER-/PR-/HER2+) 15 (12.7) 91 (16.4) 37 (29.4)
Triple-negative (ER-/PR-/HER2-) 19 (16.1) 138 (24.8) 47 (37.3)
Abbreviations: BM, brain metastases; EBC, early breast cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; IHC, 
immunohistochemistry; MBC, metastatic breast cancer; PR, progesterone receptor.
*Excluding patients with brain metastases.
†Comparing three groups (patients with EBC, patients with MBC other than BM, and patients with BM) using the chi-square test.Breast Cancer Research    Vol 10 No 1    Nam et al.
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Among the 56 HER2-positive patients, 9 of 19 patients with
ER or PR+ tumors and 12 of 37 patients with ER- and PR-
tumors received trastuzumab therapy after diagnosis of BM.
When survival analysis was performed excluding those 21
patients who received trastuzumab after the onset of BM to
eliminate the effect of trastuzumab on survival (Figure 1c, d),
Table 2
Clinical characteristics of patients with BM.
No. (%) p Value*
Total 
(n = 126)
Luminal A 
(n = 23)
Luminal B 
(n = 19)
HER2+/ER- 
(n = 37)
Triple-negative 
(n = 47)
Age, mean (range), y 47 (22–70) 46 (34–65) 48 (29–70) 48 (28–69) 47 (22–69) 0.773
Age at BM
≤ 45 years 59 (46.8) 13 (56.5) 8 (42.1) 16 (43.2) 22 (46.8) 0.746
> 45 years 67 (53.2) 10 (43.5) 11 (57.9) 21 (56.8) 25 (53.2)
AJCC stage: 0.812
I 20 (15.9) 3 (13.0) 1 (5.3) 6 (16.2) 10 (21.3)
II 34 (27.0) 6 (26.1) 7 (36.8) 8 (21.6) 13 (27.7)
III 41 (32.5) 7 (30.4) 6 (31.6) 14 (37.8) 14 (29.8)
IV 22 (17.5) 4 (17.4) 5 (26.3) 7 (18.9) 6 (12.8)
Unknown 9 (7.1) 3 (13.0) 0 (0.0) 2 (5.4) 4 (8.5)
Histology: 0.863
IDC 115 (91.3) 20 (87.0) 18 (94.7) 33 (89.0) 44 (93.6)
ILC 6 (4.8) 1 (4.3) 1 (5.3) 2 (5.4) 2 (4.3)
Mucinous 1 (0.8) 1 (4.3) 0 (0.0) 0 (0.0) 0 (0.0)
Metaplatic 4 (3.2) 1 (4.3) 0 (0.0) 2(5.4) 1 (2.1)
Disease-free interval, median (IQR), months 19.0 (25.0) 31.8(35.0) 26.9 (36.9) 17.5 (20.0) 17.0 (20.7) 0.1075
Interval from recurrence to BM, median (IQR), months 11.5 (15.2) 17.5 (36.0) 12.2 (17.0) 11.2 (14.3) 11.1 (14.5) 0.1473
Clinical features of BM: 0.053
Multiple 102 (81.0) 15 (65.2) 18 (94.7) 33 (89.2) 36 (76.6)
Single 11 (8.7) 2 (8.7) 1 (5.3) 1 (2.7) 7 (14.9)
LMD 13 (10.3) 6 (26.1) 0 (0.0) 3 (8.1) 4 (8.5)
Number of disease sites: 0.834
< 3 42 (33.3) 9 (39.1) 5 (26.3) 13 (35.1) 15 (31.9)
≥ 3 84 (67.7) 14 (60.9) 14 (73.7) 24 (64.9) 32 (68.1)
Extracranical metastatic site:
Bone 80 (63.5) 18 (78.3) 16 (84.2) 24 (64.9) 22 (46.8) 0.010
Lung/pleura 92 (73.0) 15 (65.2) 15 (78.9) 26 (70.3) 36 (76.6) 0.683
Liver 52 (41.3) 10 (43.5) 13 (68.4) 14 (37.8) 15 (31.9) 0.053
Skin/soft tissue/LN 94 (74.6) 15 (65.2) 12 (63.2) 30 (81.1) 37 (78.7) 0.122
Abbreviations: AJCC, American Joint Committee on Cancer; BM, brain metastases; ER, estrogen receptor; HER2, human epidermal growth factor 
receptor-2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IQR, interquartile range; LMD; leptomeningeal disease; LN, lymph 
node.
*Comparing four groups (luminal A, luminal B, HER2+, triple-negative) using analysis of variances to test for differences in means, Kruskall-Wallis 
test for difference in medians, and chi-square or Fisher's exact test for the remaining characteristics.Available online http://breast-cancer-research.com/content/10/1/R20
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both survival from recurrence and survival from BM still signif-
icantly differed according to breast cancer subtypes. A small
but significant survival gain in patients with luminal B (9.2
months vs 7.3 months) and HER2+/ER- (5.0 months vs 3.1
months) tumors upon delivery of trastuzumab therapy was
observed (Figure 1b, d). Moreover, a significant survival
benefit was noted in HER2-positive patients treated with tras-
tuzumab after BM was diagnosed when all 126 patients were
compared in the following three groups: 21 HER2-positive
patients who received trastuzumab after the onset of BM (12.8
months) vs 35 HER2-positive patients who did not receive
trastuzumab after the onset of BM (4.0 months) vs 70 HER2-
negative patients (3.4 months) (p = 0.0011, Figure 2).
Although patients were not randomized between those who
received trastuzumab and those who did not receive trastuzu-
mab in this retrospective analysis, patient characteristics such
as number of brain metastases, extracranial metastatic sites,
and performance status were balanced between the two
groups of HER2+ patients.
Cox regression analysis of clinical predictors
Univariate Cox regression analysis revealed a difference in sur-
vival related to hormone receptor or HER2 status. Survival after
BM was significantly poorer in triple-negatives when compared
with other types. Significant factors for survival after BM also
included age at the onset of BM (≥ 45 yrs vs < 45 yrs), the dis-
ease free interval (< 24 months vs ≥ 24 months), the interval
from the recurrence to BM (< 12 months vs ≥ 12 months),
number of metastatic sites (≥ 3 vs < 3), and leptomeningeal dis-
ease (presence vs absence) in univariate analysis. When these
significant variables for survival after BM were included in the
multivariate Cox regression model, ER- and PR-, HER2-nega-
tive, triple-negative, age ≥ 45 yrs, ≥ 3 metastatic sites, and
presence of leptomeningeal disease were each significantly
associated with poor survival after the onset of BM (Table 3).
Discussion
ER negativity, HER2 overexpression, high tumor grade and
large tumor volume of extracranial metastatic disease have all
been reported as risk factors for developing BM after breast
cancer.
More recent studies have focused on the HER2-positive
breast cancer patients, where nearly one third of patients who
received trastuzumab developed brain metastasis [15,16].
We observed a significant proportion of specific breast cancer
subtypes in our series of BM, as shown by 37% triple-negative
tumors and 29% HER2+/ER- tumors, likely as a consequence
of the aggressive nature of these subtypes. Considering the
study population was not a single cohort of patients who were
diagnosed with initial breast cancer in the same time period
and were followed over time, it is possible that the three differ-
ent groups may have been a selected population. With these
unequal factors counted, our study supports the addition of
the triple-negative subtype to the list of risk factors for devel-
oping BM. Compared to the other subtypes, the proportion of
luminal B subtypes did not vary among the three different dis-
ease status (Table 1).
Approximately 10–15% of all breast cancer presents a triple-
receptor-negative phenotype, consistent with observations
from the current study of early breast cancer. This subgroup
shares many clinical and pathological features with the so
called 'basal-like' subgroup according to gene expression pro-
file analysis, first described by Perou et al. [10]. Pathologic
characteristics of basal-like breast tumors are low expression
of HER2 and ER, high mitotic index, and high expression of
genes which are characteristic of the basal epithelial cell layer
of breast duct (myoepithelial cells), including expression of
cytokeratins 5, 6, and 17 [17]. Patients with this subtype not
only have a poor prognosis but tend to develop more visceral
metastasis, including brain metastasis, as shown in the current
study [17,18].
Once brain metastasis occurs, the outcome for breast cancer
patients is generally poor. Although radiotherapy or surgery
has been used to improve the survival and quality of life of
patients with BM, the outcome has not been generally satis-
factory. The 1-year survival rate of breast cancer patients with
BM is 20% [19], which is somewhat better than other types of
cancer owing to the relatively indolent nature of the disease.
Conventional prognostic markers affecting survival of BM
patients include age, performance status and systemic tumor
control, etc. Here, we studied the correlation between breast
cancer subtypes as well as other clinical features and the sur-
vival of breast cancer patients with BM, and the results indi-
cate that aside from the patient's age, number of extracranial
disease sites and LMD, the triple receptor status affected sur-
vival from the recurrence as well as after the development of
BM.
Figure 2
Kaplan-Meier curves of survival from brain metastasis according to  HER2 status and receipt of trastuzumab Kaplan-Meier curves of survival from brain metastasis according to 
HER2 status and receipt of trastuzumab.Breast Cancer Research    Vol 10 No 1    Nam et al.
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The prognostic implication of an intrinsic subtype or its IHC
surrogate has been previously described in early breast can-
cer patients [10-12]. Carey et al. reported on the prevalence
of IHC subtypes in correlation with survival in 469 early stage
breast cancer patients in the pre-trastuzumab era with a mini-
mum of 8.1 years of follow-up; in this study, the shortest sur-
vival was observed in patients with HER2+/ER- tumors (52%)
in contrast to 75% in the basal-like subtype, 84% in luminal A,
and 87% in luminal B [12]. Not only could the breast cancer
subtypes predict the disease recurrence and survival of EBC
patients, but such subtypes could also be used for predicting
the outcome of patients with BM as in the current study. It
must be noted that the triple-negative subtype defined in our
study contains both array-defined basal-like tumor and unclas-
sified subtypes, since we have not performed immunohisto-
chemical staining for HER1 and cytokeratin 5/6 [12]. Survival
rates from recurrence to death and from BM to death were sig-
nificantly different among breast cancer subtypes, which are
strongly rooted on the intrinsic differences in tumor biology
among breast cancer subtypes. In the current study, BM with
triple-negative tumors was associated with the gravest prog-
nosis among all the subtypes.
In the multivariate analysis, not only were the conventional
prognostic factors, including age, number of extracranial met-
astatic sites, and presence of LMD, associated with the sur-
vival from the time of BM, but also both the ER and HER2
status affected survival. The survival in patients with triple-neg-
ative disease was significantly shorter from disease recur-
rence to death compared with those with luminal A tumors
(15.5 months vs 39.6 months, p = 0.0225). The overall sur-
vival characterized by prolonged disease-free interval and
longer survival from the recurrence to death in patients with
luminal A tumors could be explained by the indolent nature of
Figure 1
Kaplan-Meier survival curves according to triple receptor status (a) from recurrence to death of all patients (n = 126), (b) from brain metastasis to  death of all patients (n = 126), (c) from recurrence to death, excluding patients who received trastuzumab after BM (n = 105), and (d) from brain  metastasis to death, excluding patients who received trastuzumab after BM (n = 105) Kaplan-Meier survival curves according to triple receptor status (a) from recurrence to death of all patients (n = 126), (b) from brain metastasis to 
death of all patients (n = 126), (c) from recurrence to death, excluding patients who received trastuzumab after BM (n = 105), and (d) from brain 
metastasis to death, excluding patients who received trastuzumab after BM (n = 105).Available online http://breast-cancer-research.com/content/10/1/R20
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the disease as well as the responsiveness to hormonal agents.
However, the survival time was as low as for triple-negatives
once the tumors in luminal A patients metastasized to the brain
(4 months vs 3.4 months, p = 0.166). This short survival is
most likely due to the lack of further therapy since BM presents
in the very late phase of the disease in the patients with luminal
A tumors. By contrast, the poor prognosis of triple-negative
tumor is likely due to its intrinsic biological aggressiveness as
well as the paucity of subsequent treatment to control the
systemic disease [17]. The present study suggests that the
patients with triple-negative tumors and HER2+/ER- tumors
may have a higher risk to develop BM than the hormone recep-
tor-positive subgroup, and no survival difference was
observed between triple-negative tumors and HER2+/ER-
tumors after excluding patients who received trastuzumab
after BM diagnosis (3.4 months vs 3.1 months, p = 0.9253).
However, patients with HER2-positive disease who received
trastuzumab lived longer (12.8 months vs 4.0 months, p =
0.0019). Consequently, triple-negative tumors have become
the worst prognostic group since the emergence of trastuzu-
mab. Although trastuzumab does not cross the blood-brain
barrier and has no direct activity on brain metastases, several
studies have shown a survival benefit with trastuzumab in
HER2-positive patients with BM, who had a significantly
longer survival time compared with HER2-negative patients
[20,21]. This improvement of survival could be largely attrib-
uted to the effects of trastuzumab in controlling systemic
metastasis. However, it must be noted that potential selection
biases dependent on the different clinical and social
circumstances for the population in this retrospective study
may have existed in prescribing trastuzumab.
Conclusion
In summary, breast cancer patients with triple-negative and
HER2+/ER- tumors appear to have a high risk for developing
brain metastasis. Breast cancer subtypes, age of the patient,
number of metastatic sites, and leptomeningeal disease were
significantly correlated with survival after the onset of BM.
Equally short survival times were observed in patients with
luminal A and triple-negative tumors compared with luminal B
and HER2+/ER- tumors after the onset of brain metastasis.
Most likely the survival time gain by the latter two HER2-posi-
tive groups was due to the use of trastuzumab therapy,
although there seemed to be an intrinsic biological difference
for survival in these two groups. Together, our results show
that ER, PR and HER2 combined receptor status could be
useful in predicting survival even after BM diagnosis. Further
studies are required to develop strategies to cover issues such
as screening, as well as management for patients with triple-
negative subtype BM.
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Table 3
Results of Cox regression analysis of survival predictors in 126 patients with BM.
Variable Univariate analysis Multivariate analysis
HR (95% CI) p Value HR (95% CI) p Value
ER- and PR- vs ER or PR+ 1.477 (1.006–2.168) 0.047 1.656 (1.107–2.478) 0.014*
HER2- vs HER2+ 1.625 (1.125–2.347) 0.010 1.608 (1.099–2.352) 0.014*
Triple negative vs others 1.758 (1.194–2.588) 0.004 1.692 (1.137–2.518) 0.010*
Age ≥ 45 yrs vs < 45 yrs 1.815 (1.245–2.647) 0.002 1.700 (1.155–2.504) 0.007†
Disease free interval: < 24 months vs ≥ 24 months 1.857 (1.258–2.740) 0.002 1.379 (0.897–2.119) 0.143†
Interval from recurrence to BM: < 12 months vs ≥ 12 months 0.688 (0.478–0.988) 0.043 0.702 (0.478–1.031) 0.071†
Number of metastatic sites: ≥ 3 vs < 3 1.710 (1.155–2.532) 0.007 1.769 (1.141–2.743) 0.011†
Leptomeningeal disease: presence vs absence 2.069 (1.153–3.713) 0.015 2.865 (1.506–5.450) 0.001†
Abbreviations: BM, brain metastasis; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; HR, hazard 
ratio; PR, progesterone receptor.
*Variables regarding triple receptor status were separately analyzed adjusting for other variables (age, disease free interval, interval from 
recurrence to BM, number of metastatic sites, leptomeningeal disease).
†Each variable other than triple receptor status was adjusted with triple-negative vs others.Breast Cancer Research    Vol 10 No 1    Nam et al.
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